Abiogen is one of the top 30 pharmaceutical companies in Italy (358 employees, turnover 2016 157 M, +16%), whose production is concentrated in the Ospedaletto facility (Pisa), where injectable, ointments, oral liquid and solid products are produced, 90% of which to meet domestic demand and the rest for contract manufacturing. The company's core business is bone metabolism pathologies, including rare diseases, in particular the osteoarticular area (three quarters of turnover) with bisphosphonates (e. g. Neridronate), then dermatology, diabetes, respiratory infections. Abiogen also carries out third-party production services (CMO), a growing activity in terms of turnover, exploiting its own certified and high-level know-how and plants. Abiogen has a programme of internationalisation towards European and non-European countries.
Abiogen, with its 358 employees, is one of the top 30 pharmaceutical companies in Italy. Despite the slowdown in the European market, consolidated revenues in 2016 grew by two figures compared to the previous year (+16%) to approximately 157 million euros. Production is concentrated in the Ospedaletto plant (Pisa), where over 37 million pieces are produced including injectable drugs (5%), oral liquids (80%), oral solids (14.5%) and ointments (0.5%), 90% of which are used to meet internal demand and the rest for contract manufacturing.
The company's core business is the pathologies of bone metabolism, (also rare diseases), in particular the osteoarticular area (three quarters of turnover) with bisphosphonates (e. g. Nerhydronate, amine-bisphosphonate used in metabolic osteopathies, the first drug to have obtained the indication for imperfect osteogenesis). In addition to the production of its own products, Abiogen carries out CMO (Contract Manufacturing Organisation) services using its own high level, certified know-how and plants. In 2011 Abiogen created Galileo Research, spin off of the R&D Division, with the aim of exploring and developing a platform based on cell therapy, entering the area of advanced therapies and developing an innovative heterologous cell therapy in the field of oncology for the treatment of ovarian cancer. Abiogen has a programme of internationalisation towards European and non-European countries.